AVAPRO TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

IRBESARTAN

থেকে পাওয়া:

SANOFI-AVENTIS CANADA INC

এটিসি কোড:

C09CA04

INN (আন্তর্জাতিক নাম):

IRBESARTAN

ডোজ:

150MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

IRBESARTAN 150MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

90

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0131700002; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

1998-06-01

পণ্য বৈশিষ্ট্য

_Product Monograph _
_ _
_AVAPRO Irbesartan _
_Page 1 of 33_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION PR
AVAPRO
®
Irbesartan tablets
Tablets, 75, 150 and 300 mg, Oral
USP
Angiotensin II AT
1
Receptor Blocker
sanofi-aventis Canada Inc.
2905 Place Louis-R.-Renaud
Laval, Quebec H7V 0A3
Date of Initial Authorization:
June 01, 1998
Date of Revision:
November 22, 2022
Submission Control Number: 265391
_Product Monograph _
_ _
_AVAPRO Irbesartan _
_Page 2 of 33_
RECENT MAJOR LABEL CHANGES
7. WARNINGS AND PRECAUTIONS
11/2020
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 4
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
..............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
......................................................... 5
4.4
Administration
..........................................................................................................
5
4.5
Missed Dose
............................